Duloxetine treatment improves sleep quality and reduces pro-inflammatory cytokine levels in patients with major depressive disorder
After 4 weeks of duloxetine treatment (40-60 mg/day), patients with MDD showed significant improvements in sleep parameters including increased total sleep time (TST) and sleep efficiency (SE), and decreased wake after sleep onset (WASO). Serum levels of IL-1β, IL-8, IL-12, and IFN-γ were significantly reduced. Baseline and post-treatment correlations suggest a link between sleep improvement and inflammatory changes.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Duloxetine treatment improves sleep quality and reduces pro-inflammatory cytokine levels in patients with major depressive disorder The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 32/100 (low).
The Claim
Duloxetine treatment improves sleep quality and reduces pro-inflammatory cytokine levels in patients with major depressive disorder
This conclusion is most relevant to: 74 patients with major depressive disorder (DSM-5 criteria, baseline HAMD-24 ≥ 20, no prior antidepressant or anti-inflammatory drug use within 3 months).
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Association between changes in sleep quality and serum pro-inflammatory cytokine levels in patients with major depressive disorder following duloxetine treatment. (Annals of general psychiatry, 2026) —
How It Works
The proposed biological pathway:
- ▸Duloxetine inhibits serotonin and norepinephrine reuptake
- ▸Reduces peripheral pro-inflammatory cytokine levels (IL-1β, IL-8, IL-12, IFN-γ)
- ▸Improves objective sleep parameters (TST, SE, WASO)
- ▸Correlation between sleep improvement and cytokine reduction suggests a link between anti-inflammatory effects and sleep regulation
Who Might Benefit
Evidence fit by population:
- ▸74 patients with major depressive disorder (DSM-5 criteria, baseline HAMD-24 ≥ 20, no prior antidepressant or anti-inflammatory drug use within 3 months)
Recommended Dose
40-60 mg daily
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Open-label design without placebo control group
- ▸Short treatment duration (4 weeks) limits generalizability to long-term effects
- ▸Small sample size (n=74) and lack of healthy control group
References
- 1.Xu Y, Gao W, Shan F, Xia Q, Liang J. “Association between changes in sleep quality and serum pro-inflammatory cytokine levels in patients with major depressive disorder following duloxetine treatment..” Annals of general psychiatry, 2026. PMID: 42366392 DOI: 10.1186/s12991-026-00689-8